Browsing by Author Hall, M

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 24  next >
Issue DateTitleAuthor(s)
7-Sep-2021Circulating tumour cells and circulating cell-free DNA in lung cancer patients: A comparison between Thoracotomy and Video-Assisted Thoracoscopic SurgeryKatopodis, P; Anikin, V; Kishore, U; Carter, T; Hall, M; Asadi, N; Polychronis, A; Karteris, E
26-Feb-2021COVID‑19 and SARS‑CoV‑2 host cell entry mediators: Expression profiling of TMRSS4 in health and diseaseKatopodis, P; Kerslake, R; Davies, J; Randeva, HS; Chatha, K; Hall, M; Spandidos, DA; Anikin, V; Polychronis, A; Robertus, JL; Kyrou, I; Karteris, E
2020Co‑expression of peripheral olfactory receptors with SARS‑CoV‑2 infection mediators: Potential implications beyond loss of smell as a COVID‑19 symptomKerslake, R; Hall, M; Randeva, H; Spandidos, D; Chatha, K; Kyrou, I; Karteris, E
17-Jul-2019Detection of Abundant Non-Haematopoietic Circulating Cancer-Related Cells in Patients with Advanced Epithelial Ovarian CancerKumar, J; Chudasama, D; Charlotee, R; Kubista, M; Sjoback, R; Chatterjee, J; Anikin, V; Karteris, E; Hall, M
2016Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitroRogers-Broadway, KR; Chudasama, D; Pados, G; Tsolakidis, D; Goumenou, A; Hall, M; Karteris, E
31-Oct-2018Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometryRogers‑Broadway, KR; Kumar, J; Sisu, C; Wander, G; Mazey, E; Jeyaneethi, J; Pados, G; Tsolakidis, D; Klonos, E; Grunt, T; Hall, M; Chatterjee, J; Karteris, E
1-Feb-2022Differential Expression of RAD51AP1 in Ovarian Cancer: Effects of siRNA In VitroFilipe, A; Chudasama, D; Kerslake, R; Jeyaneethi, J; Anikin, V; Kyrou, I; Randeva, H; Sisu, C; Hall, M; Karteris, E
24-Jul-2017Discovery and replication of SNP-SNP interactions for quantitative lipid traits in over 60,000 individualsHolzinger, ER; Verma, SS; Moore, CB; Hall, M; De, R; Gilbert-Diamond, D; Lanktree, MB; Pankratz, N; Amuzu, A; Burt, A; Dale, C; Dudek, S; Furlong, CE; Gaunt, TR; Kim, DS; Riess, H; Sivapalaratnam, S; Tragante, V; Van Iperen, EPA; Brautbar, A; Carrell, DS; Crosslin, DR; Jarvik, GP; Kuivaniemi, H; Kullo, IJ; Larson, EB; Rasmussen-Torvik, LJ; Tromp, G; Baumert, J; Cruickshanks, KJ; Farrall, M; Hingorani, AD; Hovingh, GK; Kleber, ME; Klein, BE; Klein, R; Koenig, W; Lange, LA; MOrz, W; North, KE; Charlotte Onland-Moret, N; Reiner, AP; Talmud, PJ; Van Der Schouw, YT; Wilson, JG; Kivimaki, M; Kumari, M; Moore, JH; Drenos, F; Asselbergs, FW; Keating, BJ; Ritchie, MD
2015Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation: A Single Technology Appraisal. Evidence Review Group Report to NICEGreenhalgh, J; Longworth, L; Crossan, C; Singh, J; Bagust, A; Beale, S; Richardson, M; Banks, L; Kotas, E; Hall, M
27-Dec-2022Elevated Circulating Lactate Levels and Widespread Expression of Its Cognate Receptor, Hydroxycarboxylic Acid Receptor 1 (HCAR1), in Ovarian CancerKerslake, R; Panfilov, S; Mustafa, N; Hall, M; Kyrou, I; Randeva, H; Karteris, E; Godfrey, R
2-Sep-2020H2A Histone Family Member X (H2AX) Is Upregulated in Ovarian Cancer and Demonstrates Utility as a Prognostic Biomarker in Terms of Overall SurvivalSaravi, S; Katsuta, E; Jeyaneethi, J; Amin, HA; Kaspar, M; Takabe, K; Pados, G; Drenos, F; Hall, M
10-Aug-2020Identification of Cancer-Associated Circulating Cells in Anal Cancer PatientsCarter, TJ; Jeyaneethi, J; Kumar, J; Karteris, E; Glynne-Jones, R; Hall, M
8-Nov-2017Identification of novel cancer biomarkers of prognostic value using specific gene regulatory networks (GRN): a novel role of RAD51AP1 for ovarian and lung cancersChudasama, D; Bo, V; Hall, M; Anikin, V; Jeyaneethi, J; Gregory, J; Pados, G; Tucker, A; Harvey, A; Pink, R; Karteris, E
5-May-2021Identification of Potential Bisphenol A (BPA) Exposure Biomarkers in Ovarian CancerZahra, A; Dong, Q; Hall, M; Jeyaneethi, J; Silva, E; Karteris, E; Sisu, C
15-Nov-2016Identifying gene–gene interactions that are highly associated with four quantitative lipid traits across multiple cohortsDe, R; Verma, SS; Holzinger, E; Hall, M; Burt, A; Carrell, DS; Crosslin, DR; Jarvik, GP; Kuivaniemi, H; Kullo, IJ; Lange, LA; Lanktree, MB; Larson, EB; North, KE; Reiner, AP; Tragante, V; Tromp, G; Wilson, JG; Asselbergs, FW; Drenos, F; Moore, JH; Ritchie, MD; Keating, B; Gilbert-Diamond, D
2-Feb-2022In Silico Study to predict the structural and functional consequences of SNPs on biomarkers of ovarian cancer (OC) and BPA exposure-associated OCZahra, A; Hall, M; Chatterjee, J; Sisu, C; Karteris, E
2023Investigation of the role of asprosin and downstream glycolytic molecules in ovarian cancerKerslake, Rachel
12-Sep-2019Kinase inhibitors and ovarian cancerKatopodis, P; Chudasama, D; Wander, G; Sales, L; Kumar, J; Pandhal, M; Anikin, V; Chatterjee, J; Hall, M; Karteris, E
7-Mar-2019Liquid biopsies in lung cancer: Four emerging technologies and potential clinical applicationsChudasama, D; Katopodis, P; Stone, N; Haskell, J; Sheridan, H; Gardner, B; Urnovitz, H; Schuetz, E; Beck, J; Hall, M; Barr, J; Sisu, C; Rice, A; Polychronis, A; Anikin, V; Karteris, E
9-Jul-2021A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancerKerslake, R; Hall, M; Vagnarelli, P; Jeyaneethi, J; Randeva, HS; Pados, G; Kyrou, I; Karteris, E